Clinical trials: Dexamethasone
- Drug or intervention Dexamethasone
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Adrenal Insufficiency
An Investigational Study of Hydrocortisone
This study will investigate a new drug called Infacort®; a newly-developed immediate release formulation of a well-established drug called hydrocortisone.
- Trial name
- NCT01960530
- Testing
- Hydrocortisone granules, Hydrocortisone Tablet, i.v. Hydrocortisone Injection
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Neurocrine UK Limited
Plasma Cell Myeloma
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Primary Objectives: Safety run-in Part: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) Randomized Phase 3 Part: To…
- Trial name
- NCT04270409
- Testing
- Isatuximab SAR650984, Lenalidomide, Dexamethasone
- Where
- 105 sites in United States, Australia and 22 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Sanofi
Neoplasm Malignant
Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors
Primary Objective: To evaluate tolerability and safety of SAR408701 when administered as a single agent according to the investigational medicinal product (IMP) related dose limiting toxicities (DLTs) to determine the recommended…
- Trial name
- NCT03324113
- Testing
- SAR408701, dexamethasone, naphazoline
- Where
- 3 sites in Japan
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sanofi
Hematological Malignancy
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Primary Objective: Phase 1: To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984 (Isatuximab).
- Trial name
- NCT01084252
- Testing
- Isatuximab SAR650984, Dexamethasone
- Where
- 59 sites in United States, Argentina and 15 more
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Sanofi
Osteoarthritis of the Knee
A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee
This study is a multi-center, Phase 2, open-label, 1-period, parallel study with 9 cohorts of subjects with osteoarthritis (OA) of the knee enrolled to receive single-dose of TLC599 or Dexamethasone sodium phosphate (DSP) via IA…
- Trial name
- NCT03754049
- Testing
- TLC599, DSP
- Where
- 10 sites in United States, Taiwan
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Taiwan Liposome Company
Anaphylaxis
Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis
Anaphylaxis is an acute serious allergic reaction, with multi-organ system manifestations caused by the release of chemical mediators and it is potentially fatal .
- Trial name
- NCT03523221
- Testing
- Dexamethasone Oral
- Where
- Qatar
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Urinary Tract Infections in Children, Dexamethasone
Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children
Urinary tract infection (UTI) is the most frequently occurring serious bacterial infection in young children and accounts 5 to 14% of emergency department visits Formation of renal scarring in children has been associated with…
- Conditions
- Urinary Tract Infections in Children, Dexamethasone, Kidney Scarring, Acute Pyelonephritis
- Trial name
- NCT04654507
- Testing
- Dexamethasone Oral
- Where
- Qatar
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Healthy
A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects
This is an open-label, multi-center, bilateral, human factors study designed to evaluate the utilization and safety of a novel intracanalicular insertion device in healthy subjects and to evaluate the concentration of DEXTENZA in…
- Trial name
- NCT04945824
- Testing
- Dexamethasone Ophthalmic, Dilator
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Ocular Therapeutix, Inc.
Healthy
Effect of Slow Release Hydrocortisone on Fed & Fasting Volunteers; Immediate Release on Fasting Only
The purpose of the study is to find out whether food has an effect on the way the body deals with modified release hydrocortisone, and to compare with the pharmacokinetics of immediate release hydrocortisone (fasted).
- Trial name
- NCT02408068
- Testing
- Dexamethasone, Chronocort: fasted, Immediate release hydrocortisone: fasted
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Neurocrine UK Limited
Dry Eye
The DEPOT Study (Dry Eye Prescription Options for Therapy)
Assessing DEXTENZA efficacy and safety when placed within the lower eyelid canaliculus for dry eye flares in comparison to topical loteprednol suspension.
- Trial name
- NCT04911361
- Testing
- Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Research Insight LLC
Cataract
A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%
This is a post-approval, open-label, randomized, self-controlled prospective clinical study to evaluate the safety and ocular efficacy of Dexycu in controlling postoperative ocular pain and inflammation associated with cataract…
- Trial name
- NCT04273282
- Testing
- Dexycu intracameral dexamethasone, Prednisolone Acetate
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Research Insight LLC
Chronic Allergic Conjunctivitis
OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of…
- Trial name
- NCT02062905
- Testing
- Dexamethasone
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Ocular Therapeutix, Inc.
Chronic Allergic Conjunctivitis
OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of…
- Trial name
- NCT02445326
- Testing
- Dexamethasone
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Ocular Therapeutix, Inc.
Nausea and Vomiting, Chemotherapy-Induced
A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults
GW679769 may affect liver enzymes that metabolize dexamethasone and ondansetron. This study is designed to test the safety and the extent of the GW679769 affect on dexamethasone and ondansetron levels in humans.
- Trial name
- NCT00437229
- Testing
- Casopitant (GW679769) Oral Tablets, dexamethasone, ondansetron
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
EryDex Pharmacokinetics in Healthy Volunteers
To compare the pharmacokinetic properties of two different doses of EryDex (dexamethasone sodium phosphate encapsulated in erythrocytes) given as a single infusion in healthy volunteers, based on plasma concentrations of…
- Trial name
- EryDex (NCT01925859)
- Testing
- EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Quince Therapeutics S.p.A.
Chemotherapy-Induced Nausea and Vomiting (CINV)
Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)
This study will evaluate if the mean value of brain neurokinin 1 (NK1)-receptor occupancy of participants treated with aprepitant is similar to that of participants treated with fosaprepitant at certain timepoints.
- Trial name
- NCT01111851
- Testing
- Fosaprepitant 150 mg, Aprepitant 165 mg, Aprepitant 250 mg
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject
To investigate the efficacy of symptomatic therapy with topical steroids and antihistamines for application site reaction (ASR) after administration of SPM 962 in healthy subjects
- Trial name
- NCT01737931
- Testing
- Topical steroid (Dexamethasone), Topical antihistamine (Diphenhydramine)
- Where
- 2 sites in South Korea
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Acute Otitis Media
Topical Treatment of Acute Otitis Media Through Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora
The purpose of this observational study was to evaluate the effects of a topical fluoroquinolone (antibiotic) instilled into the otic (ear) canal to treat Acute Otitis Media through Tympanostomy Tubes (AOMT) on selected bacterial…
- Trial name
- NCT01027494
- Testing
- Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension
- Where
- United States
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Allergic Conjunctivitis
To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge
The purpose of the study is to determine whether Al38583 Ophthalmic Solution is safe and effective in reducing tear eosinophil levels at 5-8 hours after Conjunctival Allergen Challenge (CAC).
- Trial name
- NCT00881673
- Testing
- AL38583 Ophthalmic Solution, Maxidex, Vehicle
- Volunteers
- healthy volunteers welcome
- Sponsor
- Alcon Research
Inflammation
Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex
Phase IV, randomized, double-masked, parallel-group clinical trial comparing the ocular tolerability and steroid-induced intraocular pressure (IOP) effects of Zylet wth that of TobraDex in healthy volunteers, when either product…
- Trial name
- NCT00532961
- Testing
- Loteprednol etabonate 0.5% and tobramycin 0.3%, Dexamethasone 0.1% and tobramycin 0.3%
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated